Harvey R Kaslow, PhD 2017-04-19T14:10:00+00:00


Back to Index
Harvey R Kaslow, PhD
Associate Professor of Physiology & Biophysics
Physiology and Biophysics
MCH 250 1333 San Pablo Street Health Sciences Campus Los Angeles
+1 323 442 1244


Recommended URLs:

Main research interest: Cancer Immunotherapy and Regulation of Immune Responses.
Cytotoxic antibodies and T lymphocytes can be generated that recognize cancer cells, but immunosuppressive factors in solid tumors frequently cause these effectors to fail to control or eliminate the cancer. Compositions are available that overcome these immunosuppressive factors but they produce toxic side-effects which can be life-threatening. There is thus a need for efficacious compositions and methods with reduced toxicity. In collaboration with the laboratory of Alan Epstein (Keck School of Medicine) candidate compositions and methods have been generated and more are under development. Patents covering some compositions and methods have issued and additional patent applications are ongoing and planned. For additional information see
Cancer Immunotherapy Research:
Patents http://www-hsc.usc.edu/~hrkaslow/Research/Patents/

Education Efforts:
Dr. Kaslow’s graduate (UCSD) work involved endocrinology and metabolism and his post-doctoral (UCSF) research focused on cell signaling mechanisms. His teaching efforts continue in those areas in graduate, medical, and pharmacy courses. Dr. Kaslow serves as:
Director, MS program in Medical Physiology
Co-chair of the Endocrinology section of the medical student curriculum.
Dr. Kaslow actively participates in the continuing refinement and revision of the medical and graduate student curricula and is developing software for the analysis and management of the curriculum.


Kawamura H, Aswad F, Minagawa M, Malone K, Kaslow H, Koch-Nolte F, Schott WH, Leiter EH, Dennert G. P2X7 receptor-dependent and -independent T cell death is induced by nicotinamide adenine dinucleotide. J Immunol. 2005 Feb 15; 174(4):1971-9. View in: PubMed

Zhu Z, Stevenson D, Ritter T, Schechter JE, Mircheff AK, Kaslow HR, Trousdale MD. Expression of IL-10 and TNF-inhibitor genes in lacrimal gland epithelial cells suppresses their ability to activate lymphocytes. Cornea. 2002 Mar; 21(2):210-4. View in: PubMed

Trousdale MD, Stevenson D, Zhu Z, Kaslow HR, Schechter JE, Warren DW, Azzarolo AM, Ritter T, Mircheff AK. Effect of anti-inflammatory cytokines on the activation of lymphocytes by lacrimal gland acinar cells in an autologous mixed cell reaction. Adv Exp Med Biol. 2002; 506(Pt B):789-94. View in: PubMed

Guo Z, Azzarolo AM, Schechter JE, Warren DW, Wood RL, Mircheff AK, Kaslow HR. Lacrimal gland epithelial cells stimulate proliferation in autologous lymphocyte preparations. Exp Eye Res. 2000 Jul; 71(1):11-22. View in: PubMed

Guo Z, Song D, Azzarolo AM, Schechter JE, Warren DW, Wood RL, Mircheff AK, Kaslow HR. Autologous lacrimal-lymphoid mixed-cell reactions induce dacryoadenitis in rabbits. Exp Eye Res. 2000 Jul; 71(1):23-31. View in: PubMed

Mircheff AK, Gierow JP, Yang T, Zhang J, Wood RL, Azzarolo AM, Warren DW, Zeng H, Guo Z, Kaslow HR, Hamm-Alvarez SF, Okamoto CT, Bachmann M. Sjögren's autoimmunity: how perturbation of recognition in endomembrane traffic may provoke pathological recognition at the cell surface. J Mol Recognit. 1998; 11(1-6):40-8. View in: PubMed

Kaslow HR, Guo Z, Warren DW, Wood RL, Mircheff AK. A method to study induction of autoimmunity in vitro: co-culture of lacrimal cells and autologous immune system cells. Adv Exp Med Biol. 1998; 438:583-9. View in: PubMed

Wang J, Nemoto E, Kots AY, Kaslow HR, Dennert G. Regulation of cytotoxic T cells by ecto-nicotinamide adenine dinucleotide (NAD) correlates with cell surface GPI-anchored/arginine ADP-ribosyltransferase. J Immunol. 1994 Nov 1; 153(9):4048-58. View in: PubMed

Sugawara S, Kaslow HR, Dennert G. CTX-B inhibits CTL cytotoxicity and cytoskeletal movements. Immunopharmacology. 1993 Sep-Oct; 26(2):93-104. View in: PubMed

Kaslow HR, Burns DL. Pertussis toxin and target eukaryotic cells: binding, entry, and activation. FASEB J. 1992 Jun; 6(9):2684-90. View in: PubMed

Kaslow HR, Platler BW, Blumberg DA, Cherry JD. Detection of antibodies inhibiting the ADP-ribosyltransferase activity of pertussis toxin in human serum. J Clin Microbiol. 1992 Jun; 30(6):1380-7. View in: PubMed

Kaslow HR, Schlotterbeck JD, Gotto J. Evaluation of antibodies elicited by immunization with pertussis toxin. Dev Biol Stand. 1991; 73:143-50. View in: PubMed

Kaslow HR, Schlotterbeck JD, Kenimer JG. Monoclonal antibodies that inhibit ADP-ribosyltransferase but not NAD-glycohydrolase activity of pertussis toxin. Infect Immun. 1990 Mar; 58(3):746-52. View in: PubMed

Bradley DC, Kaslow HR. Radiometric assays for glycerol, glucose, and glycogen. Anal Biochem. 1989 Jul; 180(1):11-6. View in: PubMed

Kaslow HR, Schlotterbeck JD, Mar VL, Burnette WN. Alkylation of cysteine 41, but not cysteine 200, decreases the ADP-ribosyltransferase activity of the S1 subunit of pertussis toxin. J Biol Chem. 1989 Apr 15; 264(11):6386-90. View in: PubMed

Antwi D, Youn JH, Shargill NS, Lesikar DD, Kaslow HR. Regulation of glycogen synthase in muscle and adipose tissue during fasting and refeeding. Am J Physiol. 1988 Jun; 254(6 Pt 1):E720-5. View in: PubMed

Kaslow HR, Lesikar DD. Sulfhydryl-alkylating reagents inactivate the NAD glycohydrolase activity of pertussis toxin. Biochemistry. 1987 Jul 14; 26(14):4397-402. View in: PubMed

Powered bySC CTSI